Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: January 2007
-
By Kevin Noonan — Illustrating once again distinctions between permanent and preliminary injunctions in its jurisprudence, the Federal Circuit used a combination of its patent-specific precedent and regional circuit law to affirm a preliminary injunction against only one of three co-defendants. In Abbott Lab. v. Andrx Pharm., Inc., the Court held that one…
-
By Robert Dailey — Last Friday the Federal Circuit refused Ariad's request to hear its appeal of a pre-trial ruling in its district court litigation with Amgen. In mid-2006, Amgen filed a declaratory judgment action against Ariad in the U.S. District Court for the District of Delaware. Ariad responded by asking Judge Kent Jordan…
-
By Jason Derry — Genentech and Seattle Genetics have announced an agreement involving the development and commercialization of a humanized monoclonal antibody for treating hematologic malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. The antibody, SGN-40, is currently in Phase I and II clinical trials. According to the press release, Seattle…
-
Innogenetics Wins $7 Million Judgment Against Abbott for Infringing HCV Genotyping Method By Robert Dailey — Judge Barbara Crabb, in an opinion issued last week, rejected all of Abbott's post-trial motions and upheld an earlier $7 million verdict against its diagnostics division for infringing an Innogenetics patent. Innogenetics owns U.S. Patent Number 5,846,704…
-
By Christopher P. Singer — In a January 2, 2007 press release, The Patent Board® announced that it will provide The Patent Scorecard to The Wall Street Journal on a weekly basis. The Wall Street Journal plans to publish the information every Tuesday in the "Money & Investing" section, and will be accessible…
-
By Jason Derry — Roche Holding AG has announced an agreement with Synosis Therapeutics in which Synosis will have rights to five drug candidates that Roche is no longer developing. Four of the drugs are in Phase I clinical trials. According to the Press Release, the drugs relate to schizophrenia, cognitive disorders, Parkinson's…
-
By Jason Derry — Elusys Therapeutics, Inc. has announced an exclusive license with Pfizer Inc. to collaborate in the development of new therapeutics for infectious diseases. The agreement relates to the use of Elusys' HP Antibody® technology. Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular…
-
By Jason Derry — Ecopia BioSciences Inc. and Caprion Pharmaceuticals Inc. have announced the intent to merge and form a new company that will focus on oncology and infectious disease. Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
-
By Jason Derry — Pharmacopeia and Wyeth have announced that the two companies have agreed to an exclusive license relating to the development and commercialization of therapeutics from Pharmacopeia's JAK3 inhibitor technology. Under the agreement, Pharmacopeia has the right to therapeutics relating to dermatological and ocular diseases by topical administration, while Wyeth has…
-
By Mark Chael — In an opinion by Circuit Judges Prost and Dyk handed down on December 29, 2006, the U.S. Court of Appeals for the Federal Circuit held that the U.S. District Court for the District of Arizona had incorrectly construed the claim term "dispensing" in U.S. Patent No. 6,352,861 (the '861 patent)…
Patent Docs 